Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Liabilities (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Total Liabilities data on record, last reported at $177.3 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 150.48% year-over-year to $177.3 million; the TTM value through Dec 2025 reached $177.3 million, up 150.48%, while the annual FY2025 figure was $177.3 million, 150.48% up from the prior year.
  • Total Liabilities reached $177.3 million in Q4 2025 per VRDN's latest filing, up from $74.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $177.3 million in Q4 2025 and bottomed at -$604.5 million in Q1 2025.
  • Average Total Liabilities over 5 years is $15.2 million, with a median of $38.1 million recorded in 2022.
  • The widest YoY moves for Total Liabilities: up 150.48% in 2025, down 1363.24% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $16.0 million in 2021, then soared by 150.28% to $40.0 million in 2022, then rose by 20.92% to $48.4 million in 2023, then skyrocketed by 46.2% to $70.8 million in 2024, then skyrocketed by 150.48% to $177.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $177.3 million in Q4 2025, $74.2 million in Q3 2025, and $67.2 million in Q2 2025.